Literature DB >> 14647056

Sampling variability of liver fibrosis in chronic hepatitis C.

Pierre Bedossa1, Delphine Dargère, Valerie Paradis.   

Abstract

Fibrosis is a common endpoint of clinical trials in chronic hepatitis C, and liver biopsy remains the gold standard for fibrosis evaluation. However, variability in the distribution of fibrosis within the liver is a potential limitation. Our aim was to assess the heterogeneity of liver fibrosis and its influence on the accuracy of assessment of fibrosis with liver biopsy. Surgical samples of livers from patients with chronic hepatitis C were studied. Measurement of fibrosis was performed on the whole section by using both image analysis and METAVIR score (reference value). From the digitized image of the whole section, virtual biopsy specimens of increasing length were produced. Fibrosis was assessed independently on each individual virtual biopsy specimen. Results were compared with the reference value according to the length of the biopsy specimen. By using image analysis, the coefficient of variation of fibrosis measurement with 15-mm long biopsy specimens was 55%; and for biopsy specimens of 25-mm length it was 45%. By using the METAVIR scoring system, 65% of biopsies 15 mm in length were categorized correctly according to the reference value. This increased to 75% for a 25-mm liver biopsy specimen without any substantial benefit for longer biopsy specimens. Sampling variability of fibrosis is a significant limitation in the assessment of fibrosis with liver biopsy. In conclusion, this study suggests that a length of at least 25 mm is necessary to evaluate fibrosis accurately with a semiquantitative score. Sampling variability becomes a major limitation when using more accurate methods such as automated image analysis.

Entities:  

Mesh:

Year:  2003        PMID: 14647056     DOI: 10.1016/j.hep.2003.09.022

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  583 in total

1.  Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

Authors:  Donna L White; Ali Hashmi; David J Ramsey; Jill Kuzniarek; Shahriar Tavakoli-Tabasi; Hashem B El-Serag
Journal:  Dig Dis Sci       Date:  2012-06-05       Impact factor: 3.199

2.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

3.  FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

Authors:  Keyur Patel; Mireen Friedrich-Rust; Yoav Lurie; Mircea Grigorescu; Carol Stanciu; Chuan-Mo Lee; Eugene R Schiff; Dieter Häussinger; Michael P Manns; Guido Gerken; Isabelle Colle; Michael Torbenson; Erik Pulkstenis; G Mani Subramanian; John G McHutchison; Stefan Zeuzem
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

4.  Magnetic resonance elastography SE-EPI vs GRE sequences at 3T in a pediatric population with liver disease.

Authors:  Juan S Calle-Toro; Suraj D Serai; Erum A Hartung; David J Goldberg; Bradley D Bolster; Kassa Darge; Sudha A Anupindi
Journal:  Abdom Radiol (NY)       Date:  2019-03

5.  Detection of novel biomarkers of liver cirrhosis by proteomic analysis.

Authors:  Christian Mölleken; Barbara Sitek; Corinna Henkel; Gereon Poschmann; Bence Sipos; Sebastian Wiese; Bettina Warscheid; Christoph Broelsch; Markus Reiser; Scott L Friedman; Ida Tornøe; Anders Schlosser; Günter Klöppel; Wolff Schmiegel; Helmut E Meyer; Uffe Holmskov; Kai Stühler
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

6.  qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients.

Authors:  Shuoyu Xu; Yan Wang; Dean C S Tai; Shi Wang; Chee Leong Cheng; Qiwen Peng; Jie Yan; Yongpeng Chen; Jian Sun; Xieer Liang; Youfu Zhu; Jagath C Rajapakse; Roy E Welsch; Peter T C So; Aileen Wee; Jinlin Hou; Hanry Yu
Journal:  J Hepatol       Date:  2014-02-26       Impact factor: 25.083

7.  3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.

Authors:  Chun-Yu Zhang; Qian Zhang; Hui-Mao Zhang; Hai-Shan Yang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

8.  Risk factors and serological markers of liver cirrhosis after Fontan procedure.

Authors:  Mikiko Shimizu; Kenji Miyamoto; Yunosuke Nishihara; Gaku Izumi; Shuji Sakai; Kei Inai; Toshio Nishikawa; Toshio Nakanishi
Journal:  Heart Vessels       Date:  2015-09-19       Impact factor: 2.037

9.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.

Authors:  An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Radiology       Date:  2013-02-04       Impact factor: 11.105

10.  Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.

Authors:  Gregory D Kirk; Jacquie Astemborski; Shruti H Mehta; Chuck Spoler; Cedric Fisher; Danisha Allen; Yvonne Higgins; Richard D Moore; Nezem Afdhal; Michael Torbenson; Mark Sulkowski; David L Thomas
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.